Akoya Biosciences Inc (AKYA)
3.14
-0.07
(-2.18%)
USD |
NASDAQ |
Nov 14, 16:00
2.44
-0.70
(-22.29%)
After-Hours: 20:00
Akoya Biosciences Research and Development Expense (Quarterly): 5.288M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 5.288M |
| March 31, 2024 | 5.554M |
| December 31, 2023 | 4.67M |
| September 30, 2023 | 5.173M |
| June 30, 2023 | 6.923M |
| March 31, 2023 | 6.378M |
| December 31, 2022 | 6.433M |
| September 30, 2022 | 5.466M |
| June 30, 2022 | 5.598M |
| Date | Value |
|---|---|
| March 31, 2022 | 5.714M |
| December 31, 2021 | 5.563M |
| September 30, 2021 | 3.999M |
| June 30, 2021 | 2.947M |
| March 31, 2021 | 3.192M |
| December 31, 2020 | 2.532M |
| September 30, 2020 | 2.279M |
| June 30, 2020 | 2.42M |
| March 31, 2020 | 2.372M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.279M
Minimum
Sep 2020
6.923M
Maximum
Jun 2023
4.583M
Average
5.230M
Median
Research and Development Expense (Quarterly) Benchmarks
| Bruker Corp | 98.10M |
| Azenta Inc | 7.913M |
| Harvard Bioscience Inc | 2.567M |
| Bionano Genomics Inc | 6.831M |
| Singular Genomics Systems Inc | 10.73M |